Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PITHAC: Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin for Pleural Carcinosis
NCT06281860Phase 1Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cisplatin in pleural carcinomatosis (5 arms). Primary endpoint: Dose Limiting Toxicities at 18 months. Started Nov 2023; status: recruiting.
02
Drugs
cisplatin
03
Conditions
pleural carcinomatosis
Beyond the preview
Go deeper on NCT06281860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281860.